Center for Immunity and Immunotherapies
As world leaders in gene therapy and editing, cellular therapy and protein therapeutics, the Center for Immunity and Immunotherapies (CIIT) is pioneering research that could revolutionize treatment for hundreds of rare and common genetic disorders, curing disease at the source.
CIIT researchers are working toward a day when kids won’t need these lifelong treatments. Instead, they’ll get a cell therapy — a single infusion of cells that addresses a disease’s cause and, ideally, cures it forever.
Our immunology teams have led over 20 cutting-edge clinical research trials for patients with therapeutics discovered at Seattle Children’s Research Institute.
We’re leading novel gene therapy clinical trials for pediatric disorders including X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, congenital neutropenia and severe combined immune deficiency.
Seattle Children’s is one of the few places in the world where bench-to-bedside immunology experts are both conducting research and providing treatment for more than 400 primary immune deficiency disorders.
Our understanding of immune diseases and disorders has been revolutionized by the advances in genome science and other technologies over the last two decades. There are now more than 500 single gene disorders that lead to immunodeficiency and/or autoimmunity, making our patient population likely the most complex within any pediatric subspecialty.
— Dr. David Rawlings, immunologist and director of the Center for Immunity and Immunotherapies, chief of the Division of Immunology, Seattle Children's
Explore CIIT
Find a Research Study or Clinical Trial
CIIT researchers are launching some of the world’s first clinical trials of gene therapies for pediatric disorders, bringing gene therapies from the lab to patients. Learn about participating in research.